Amicus Therapeutics (FOLD) on Sunday reported preliminary Q4 revenue of $149.9 million.
Analysts polled by FactSet expect $147.5 million.
For full-year 2025, the company expects revenue to grow between 17% and 24% at a constant exchange rate.
The company also projects positive net income for the second half of 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.